ReviewJournal of internal medicine2024
Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Xiaokun Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this papercites it
ReviewJournal of internal medicine2024
Xiaokun Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.